Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Co. Ltd ADR (TAK)

Takeda Pharmaceutical Co. Ltd ADR (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,284,064
  • Shares Outstanding, K 3,164,505
  • Annual Sales, $ 31,764 M
  • Annual Income, $ 2,048 M
  • 60-Month Beta 0.73
  • Price/Sales 1.42
  • Price/Cash Flow 4.07
  • Price/Book 0.89
Trade TAK with:

Options Overview Details

View History
  • Implied Volatility 23.29% ( +1.67%)
  • Historical Volatility 22.37%
  • IV Percentile 31%
  • IV Rank 25.13%
  • IV High 36.20% on 12/31/21
  • IV Low 18.96% on 05/26/21
  • Put/Call Vol Ratio 1.67
  • Today's Volume 8
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 15,084
  • Open Int (30-Day) 14,777

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.51
  • Growth Rate Est. (year over year) +195,782.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.92 +2.44%
on 05/12/22
14.76 -3.39%
on 05/04/22
-0.44 (-2.99%)
since 04/18/22
3-Month
13.92 +2.44%
on 05/12/22
15.28 -6.68%
on 02/28/22
-1.09 (-7.10%)
since 02/18/22
52-Week
13.17 +8.28%
on 12/01/21
17.56 -18.79%
on 05/21/21
-2.98 (-17.29%)
since 05/18/21

Most Recent Stories

More News
3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure,...

GILD : 63.37 (+0.30%)
GSK : 44.20 (-1.14%)
TAK : 14.23 (-0.56%)
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

Takeda ( TOKYO:4502/NYSE:TAK ) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength...

TAK : 14.23 (-0.56%)
5 Resilient Dividend Stocks to Buy and Hold

Yesterday, the Federal Reserve implemented its first 50-basis-point interest rate hike since 2000 to tame rising inflation. The volatility in the stock market has been increasing with the Fed’s monetary...

MPC : 95.38 (-2.22%)
OLN : 63.94 (-1.98%)
SU : 37.72 (-1.64%)
TAK : 14.23 (-0.56%)
WM : 155.43 (-1.14%)
How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction....

BAYRY : 16.8400 (-0.65%)
BMY : 77.65 (-0.73%)
TAK : 14.23 (-0.56%)
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories

Takeda ( TSE:4502/NYSE:TAK ) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for...

TAK : 14.23 (-0.56%)
Does Novavax's Latest Approval Change Anything for Shareholders?

The approval of Novavax's COVID vaccine in Japan would be more notable had the company's 2021 vaccine rollout gone according to plan.

NVAX : 51.84 (-0.21%)
TAK : 14.23 (-0.56%)
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the...

TAK : 14.23 (-0.56%)
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine

NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine

NVAX : 51.84 (-0.21%)
MRNA : 142.65 (+0.26%)
PFE : 50.84 (-0.97%)
TAK : 14.23 (-0.56%)
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan

Takeda (TSE:4502/NYSE:TAK) today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid® Intramuscular Injection...

TAK : 14.23 (-0.56%)
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

Takeda ( TSE:4502/NYSE:TAK ) today announced TAKHZYRO ® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in...

TAK : 14.23 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 14.46
2nd Resistance Point 14.40
1st Resistance Point 14.36
Last Price 14.23
1st Support Level 14.26
2nd Support Level 14.20
3rd Support Level 14.16

See More

52-Week High 17.56
Fibonacci 61.8% 15.88
Fibonacci 50% 15.36
Fibonacci 38.2% 14.85
Last Price 14.23
52-Week Low 13.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar